RenovoRx advances TAMP into borderline resectable pancreatic cancer; first patient enrolled
RenovoRx is advancing TAMP™ into borderline resectable pancreatic cancer, with the first patient enrolled in the investigator-initiated PRISM-TAMP trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.